← boardnext 2028-12
KMDA
Kamada, Ltd.distress 0/10 · well-funded / low risk$7.000%today-25% from 52w high
Lead: Alpha 1-Antitrypsin Deficiency
Revenue
$45M
Liquidity
$73M
Runway
—
Shares 1y
0%
Price & events
-9.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
+1.3%
1W
-1.8%
1M
-15.4%
3M
-8.9%
6M
-8.8%
1Y
+26.2%
2Y
+33.4%
5Y
+14.5%
All
Overview
- Market Cap
- $403.80M
- Volume
- 3.07K
- 52 Week Range
- $6.60 – $9.31
- Total Shares
- 57.69M
- Float Shares
- 31.45M
- Short %
- 0.49%
- % Held by Insiders
- 7.20%
- % Held by Institutions
- 48.60%
- RVOL
- 0.09x
- Beta
- 0.15
Pipeline stages · 1 programs
Alpha 1-Antitrypsin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | Alpha 1-Antitrypsin | Alpha 1-Antitrypsin Deficiency | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 57,686,056 · 0 offerings/1y · 0 PIPEs
- 2024-11-14SC 13G/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $13 (+86% upside) · 4 analysts
- 2025-12-09HC Wainwright & Co.Buy
- 2025-05-15BenchmarkBuy
- 2025-03-21BenchmarkBuy
- 2025-03-06HC Wainwright & Co.Buy
- 2025-01-10HC Wainwright & Co.Buy
- 2024-11-14HC Wainwright & Co.Buy
Competitors — Alpha 1-Antitrypsin Deficiency
Recent news
- 2026-07-22Kamada stock trades steadily as plasma-derived therapies support revenue growth - Ad-hoc-news.de
- 2026-07-22Kamada stock holds at Buy as Benchmark cites $50M plasma deal - Investing.com UK
- 2026-07-21Kamada stock holds at Buy as Benchmark cites $50M plasma deal - Investing.com Canada
- 2026-07-20Kamada (KMDA) Secures $50M Plasma Supply Agreement - GuruFocus
- 2026-07-20Kamada secures $50M plasma supply deal over three years - Investing.com
- 2026-07-20Kamada Ltd. (NASDAQ: KMDA) signs three-year $50M plasma supply agreement - Stock Titan
- 2026-07-20Press Release: Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company Focused on Plasma-derived Therapies - Moomoo
- 2026-07-20Kamada’s centers plan ~50,000 liters of plasma each at full capacity - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.